177
Views
18
CrossRef citations to date
0
Altmetric
Research Article

Sanggenon C and O inhibit NO production, iNOS expression and NF-κB activation in LPS-induced RAW264.7 cells

, , , &
Pages 84-88 | Received 03 Mar 2011, Accepted 11 Apr 2011, Published online: 26 May 2011
 

Abstract

Objective: The NO production through the iNOS induction by activation of nuclear factor (NF-κB) is known to involve in various inflammatory conditions. Sanggenon C and O, two Diels-Alder type adducts isolated from Morus alba, a plant has been used for the anti-inflammatory purpose in the Oriental medicine, were investigated for their effect on the NO production, iNOS expression and NF-κB activity.

Methods: The inhibitory effects of sanggenon C and O on the NF-κB activity were investigated in LPS-stimulated RAW264.7 cells by SEAP reporter assay. The regulation of the iNOS expression and IκBα activation by two compounds was also evaluated by Western blot.

Results: Both compounds strongly inhibited NO production and NF-κB activation in a dose-dependent manner. The expression of the iNOS protein was also suppressed by treatment of the compounds (10 and 1 µM). Sanggenon O showed stronger inhibition than the diastereomer sanggenon C. Both compounds prevented the phosphorylation and degradation of IκBα protein.

Conclusion: We demonstrated that sanggenon C and O inhibited NO production and iNOS expression by suppressing NF-κB activity and IκBα activation.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.